| Catalog No | Package | Original Price | Price | Inventory | Quantity | Operating |
|---|---|---|---|---|---|---|
| BP5116-5mg | 5mg | $350.00 | Sign in |
|
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
Dihydrodehydrodiconiferyl alcohol (7R,8S-Dihydrodehydrodiconiferyl alcohol, CAS No. 126253-41-6) is a naturally occurring lignin unit derivative and belongs to the guaiacin compound family. As the antiantimer of (2R,3S)-dihydrodehydrodespinol, dihydroerythritol mainly acts as one of the lignin components in plants, participating in the structural construction of plant cell walls. In recent years, with the rapid development of natural product pharmacology, dihydroerythritol has attracted widespread attention, especially due to its unique molecular structure and excellent bioactivity, showing significant potential in skin moisturizing and skin barrier repair.
This paper aims to systematically review the chemical structure and physicochemical properties of dihydroerythritol, its plant origins and extraction methods, explore its pharmacological activity and mechanism of action in depth, evaluate its druggability and pharmacokinetic characteristics, and anticipate its potential and development direction in clinical applications, striving to provide comprehensive and in-depth scientific evidence for related research.
The chemical structure of dihydroerythritol is based on the guaiacol framework, specifically as the stereoisomer of (7R,8S)-dihydrodehydrodesupenol. Its molecular formula is C20H24O6, and its molecular weight is 360.4060. Its structure contains two benzene rings and one 1-benzofuran ring. The molecule contains multiple hydroxyl groups (primary alcohol functional groups) and ether bonds, giving it strong polarity and hydrogen bond formation capabilities.
In terms of physicochemical properties, the LogP value of dihydroerythritol is 2.4212, indicating moderate lipid solubility, which facilitates penetration of biofilms without excessive hydrophobicity. Its topological pole surface area (TPSA) is 88.38 Ų, indicating certain polarity that facilitates interactions with aqueous phases and biological macromolecules. Water solubility is 0.2091 mg/mL, which is not high but sufficient to support dissolution and distribution within living organisms. The high permeability of the blood-brain barrier indicates that its molecules can cross the central nervous system barrier, indicating potential for nervous system effects. The hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity, while the Ames mutagenic test result was 0.0, indicating an extremely low genotoxicity risk.
In summary, dihydroerythritol exhibits good medicinal chemical properties, making it suitable for further pharmacological and pharmacokinetic studies.
Dihydroerythritol is mainly found in various lignin-rich plants, especially the xylem of pine family and certain angiosperms. As one of the structural units of lignin, although its content is lower than that of major monomers such as guaiacol and p-hydroxyphenylpropanol, it plays a key role in plant cell walls.
Common plant sources include coniferous species such as Pinus spp. and Abies spp., as well as some broadleaf trees. During extraction, organic solvents (such as methanol, ethanol, ethyl acetate) are typically used to extract the plant xylem, followed by separation and purification using liquid-liquid partitioning, column chromatography, and reversed-phase high-performance liquid chromatography (RP-HPLC).
In recent years, ultrasound-assisted extraction and supercritical CO2 extraction technologies have been introduced to improve extraction efficiency and purity, while reducing solvent usage and environmental impact. After purification, dihydroerythritol is structurally identified using mass spectrometry (MS), nuclear magnetic resonance imaging (NMR), and infrared spectroscopy (IR) to ensure its purity and structural accuracy.
Research on the pharmacological activity of dihydroerythritol mainly focuses on skin moisturizing and regulating skin barrier function. As a natural guaiacol derivative, it has the potential to have antioxidant, anti-inflammatory, and enhanced skin cell function.
Multiple in vitro and in vivo studies have shown that dihydroerythritol can significantly improve the hydration status of the skin's stratum corneum. By regulating the expression of skin-related genes, it promotes the synthesis of natural moisturizing factors (NMF) and hyaluronic acid, thereby enhancing the skin's moisturizing ability.
Dihydroerythritol has excellent free radical scavenging ability, which can inhibit lipid peroxide formation and reduce oxidative stress damage to skin cells. Additionally, it inhibits the expression of inflammatory factors such as TNF-α and IL-1β, helping to alleviate skin inflammation.
By regulating the expression of tight-connective proteins between cells (such as CLDN1) and keratinocyte differentiation-related proteins (such as FLG), dihydroerythritol promotes the structural integrity and functional restoration of the skin barrier, enhancing the skin's resistance to external stimuli.
The moisturizing and barrier repair effects of erythritol mainly achieve this by regulating multiple key molecular targets:
AQP3 (Aquaporin 3): AQP3 is responsible for the transport of moisture and glycerol in the skin, maintaining hydration in the stratum corneum. Dihydroerythritol can upregulate AQP3 expression, promoting the water balance inside and outside skin cells.
FLG (Filigin): FLG is an important protein for differentiating keratinocytes, and its breakdown products provide precursors for the skin's natural moisturizing factors. Dihydroerythritol promotes the expression of the FLG gene, enhancing skin moisturizing function.
CLDN1 (Tight Junction Protein 1): CLDN1 is a key component for tight intercellular junctions, maintaining the physical integrity of the skin barrier. Dihydroerythritol strengthens the skin barrier structure by promoting CLDN1 expression.
HAS2 (Hyaluronic Acid Synthase 2): HAS2 catalyzes the synthesis of hyaluronic acid, an important moisturizing factor for the skin. Dihydroerythritol enhances HAS2 activity and increases skin hyaluronic acid content.
CASQ1 (sarcoplasmic calcium-binding protein 1): Although CASQ1 is mainly expressed in muscle tissue, its potential regulatory effects in skin cells are still under study. Preliminary data suggest that dihydroerythritol may affect intracellular calcium homeostasis, indirectly modulating skin cell function.
Through multiple regulatory actions targeting these points, dihydroerythritol achieves comprehensive regulation of skin water metabolism, barrier repair, and anti-inflammatory and antioxidant effects, highlighting its unique advantages as a skin moisturizing active ingredient.
Druggability evaluations of dihydroerythritol indicate that it has promising potential for drug development:
Molecular weight and lipid solubility: The molecular weight of 360.4 Da and a moderate LogP value (2.42) comply with the Lipinski rule, facilitating oral absorption and skin penetration.
Polarity and solubility: TPSA is 88.38 Ų, with moderate water solubility, supporting its distribution and targeting in body fluids.
Safety: hERG channel inhibition is negative and Ames tests show no mutagenicity, indicating low cardiotoxicity and genotoxicity risk, with good safety.
Blood-brain barrier permeability: High blood-brain barrier permeability offers potential for central nervous system applications, but concerns about the risk of central nervous system side effects are also necessary.
In terms of pharmacokinetics, current research is relatively limited. Preliminary in vitro metabolic experiments indicate that dihydroerythritol is metabolically stable in hepatic microsomes and is mainly excreted through phase II metabolic pathways (such as glucuronic acid binding). Its bioavailability and distribution characteristics need to be further clarified through animal models and preclinical studies.
Due to its remarkable skin moisturizing and barrier-repairing activities, dihydroerythritol has broad application prospects in skin care and treatment. Specific directions include:
Skincare ingredients: As a natural active moisturizer, dihydroerythritol can be developed as a core ingredient in high-efficiency moisturizers, lotions, and other skincare products, meeting market demand for natural, safe, and effective skincare products.
Adjunctive therapy for skin diseases: For dry skin diseases, eczema, psoriasis, and other skin barrier disorders, dihydroerythritol can be used as an adjunct treatment ingredient to promote skin barrier repair and inflammation relief.
Potential for combination therapy: Combined with other anti-inflammatory and antioxidant natural products, dihydroerythritol is expected to exert synergistic effects and enhance therapeutic outcomes.
Future research should focus on its in vivo pharmacokinetic characteristics, long-term safety evaluation, and clinical efficacy validation, promoting its transition from laboratory research to clinical application.
Additionally, given its high blood-brain barrier permeability, exploring the potential applications of dihydroerythritol in neuroprotective or neuroinflammatory diseases is also worth considering.
Dihydroerythritol, as a natural guaiacol derivative with a unique structure and multiple bioactivities, demonstrates significant pharmacological value in skin moisturizing and barrier repair. Its excellent druggability parameters and safety characteristics provide a solid foundation for subsequent development. In the future, through systematic pharmacokinetic research and clinical validation, dihydroerythritol is expected to become a star molecule in the field of natural product pharmacology, promoting the widespread application of natural products in skin disease prevention and beauty care.
In summary, dihydroerythritol not only enriches the pharmacological activity spectrum of natural products but also provides new ideas and directions for natural product drug development, worthy of ongoing attention and in-depth exploration by the scientific research and industry sectors.
